Abstract:The design of the traditional Medicare benefit has changed very little since its inception in the 1960s. Enrollees in traditional Medicare can seek care from any clinicians, practices, or health care organizations (hereafter, providers) enrolled in the Medicare program and have unrestricted access to Medicare's covered services. While these benefits are appealing, beneficiary cost sharing is often high. Medicare Advantage addresses limitations of traditional Medicare by reducing cost sharing and setting maximum out-of-pocket cost caps, while also offering additional services (eg, vision, dental). Medicare Advantage plans can provide more generous benefits because they apply strong benefit design policies, including constraining their provider networks and imposing coverage restrictions (such as prior authorization). As enrollment in Medicare Advantage increases—now more than 50% of Medicare beneficiaries are enrolled in Medicare Advantage—researchers have sought to understand the strengths and weaknesses of traditional Medicare and Medicare Advantage and their implications for patients. Elsewhere in JAMA Network Open , Kalidindi and colleagues 1 compared resource use and quality of care for Medicare Advantage vs traditional Medicare enrollees who were undergoing chemotherapy for cancer. They found lower resource use in Medicare Advantage that was primarily associated with savings on physician-administered chemotherapy due to using less expensive chemotherapy regimens and fewer chemotherapy administration visits. The very high and rising spending on oncology drugs relative to other drugs 2 may provide an opportunity to improve the value of care, particularly given the substantial variation in prices for different oncology drugs. Research has demonstrated that plan and patient spending for different guideline-concordant regimens of similar efficacy differs by orders of magnitude. 3 In recent years, spending on infused and oral anticancer drugs accounted for approximately two-thirds of all spending for patients undergoing chemotherapy. 4 If Medicare Advantage plans can prompt the use of lower-priced drugs, they may realize substantial savings. 5 Under fee-for-service compensation models, oncologists are reimbursed for physician-administered drugs based on a percentage of the drug's cost (6% of the average sales price for Medicare). To counteract this incentive to use higher-priced drugs, Medicare Advantage is equipped with utilization management tools. Medicare Advantage plans can—and do—require prescribers to submit prior authorization requests before the plan will approve treatment coverage. They also may implement step therapy and quantity limits. Plans' use of utilization management is increasing, in part due to limited alternatives to control the high prices of drugs and other services. Carefully considered prior authorization policies may be an important tool in improving cancer care value given the extraordinarily high cost of cancer drugs, the wide variation in costs of guideline-supported treatment, and the urgent problem of financial toxicity for cancer patients. Utilization management can reduce resource use, but at a cost. Prior authorization processes impose administrative burdens that may limit access to potentially important medications (not assessed in this study, which included patients already receiving chemotherapy), and it leads to delayed or discontinued care among patients already taking cancer drugs. 6 ,7 Moreover, clinician burnout is a worsening challenge, and physicians are distressed by the rising administrative burden of prior authorization. This dynamic is concerning for patient care in the longer term. Innovation in the design of Medicare coverage for all beneficiaries remains a policy priority. For example, alternative payment models, such as the Oncology Care Model (OCM), have incorporated incentives to use less expensive drugs. OCM practices saw swifter uptake of biosimilar therapies and higher-value use of supportive care drugs, 4 suggesting there may be tools to influence prescribing that are more clinician-friendly than prior authorization. The fewer chemotherapy administration visits for Medicare Advantage beneficiaries observed by Kalindi and colleagues 1 raise questions as to whether plans required less frequent dosing schedules or prioritized chemotherapy regimens with less frequent administration schedules; this is an important question for future study. Another important strategy used by Medicare Advantage plans to lower resource use is defined provider networks. Medicare Advantage plans may seek to steer patients to providers with less-resource intensive practice styles. Alternatively, such networks could result if providers find the utilization management practices of Medicare Advantage plans too onerous. Evidence from Medi -Abstract Truncated-

Going off Pathway: Problem or Good Care?

Current Regulatory Status in China of Drugs Withdrawn from the US FDA Accelerated Pathway: Implications for Regulation Globally

Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid Tumors

Opportunity cost of oncology subspecialist opinion.

Evolving oncology care management trends in the United States: A survey among health care decision makers

Using Oncology Treatment Pathway Data to Evaluate Serious Illness Communication, Care Utilization, and End-of-Life Care for Patients With Cancer

Physician justification for anti-cancer treatment decisions in the evolving oncology market.

A systematic analysis of off-label drug use in real-world data (RWD) across more than 145,000 cancer patients.

Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists

Clinical pharmacist prescription review and modification for oral antineoplastic medications at an academic medical center.

Effects of Pharmacist-Led Clinical Pathway/Order Sets on Cancer Patients: A Systematic Review

Disparities in cancer care: Is there a benefit for increased use of inpatient chemotherapy (IPC) in safety-net hospitals?

How automated insurance authorization affects transparency, provider burden, and payer policies and processes: The true impact of prior authorization.

Estimating oncologist variability in prescribing systemic cancer therapies to patients in the last 30 days of life

The Promise and Perils of Oncology Care in Medicare Advantage

Treatment rates and reasons for non-treatment in a real-world cohort of patients with pancreatic cancer.

Impacts of Pharmacists-Managed Oncology Outpatient Clinic on Resolving Drug-Related Problems in Ambulatory Neoplasm Patients: A Prospective Study in China

Patterns of care in the management of high-risk COPD in the US (2011-2019): an observational study for the CONQUEST quality improvement program

Importance of Patient Health Insurance Coverage and Out-of-Pocket Costs for Genomic Testing in Oncologists' Treatment Decisions

Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.

Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment